SynthesisThe oncologist2026

Risk of venous thromboembolism with CDK4/6 inhibitor use in breast cancer: a systematic review and meta-analysis.

Elysa Cortez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.